Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers

NCT00667810 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00667810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
August 31, 2013
Enrollment
901 (actual)
Sites
346

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease